MedinCell Gets ISS ESG Prime Rating for Strong CSR

Published on:
by KnowESG
KnowESG_CSR
Image courtesy of blog.submittable.com

Institutional Shareholder Services (ISS) awarded MedinCell a “Prime” Environmental, Social, and Governance (ESG) rating.

The rating places MedinCell among the top 10% in the Pharmaceuticals & Biotechnology sector.

ISS, one of the world’s leading rating agencies for sustainable investments, provides a highly relevant, material assessment of ESG performance to investors.

MedinCell is a pharmaceutical technology company with 150 employees from 30 nationalities, all shareholders.

The first product based on Medincell’s long-acting injectable technology should get FDA market approval by April 2023, two additional products are in phase 3, and a pipeline of other products follows.

For more investor-related news

Source: MedinCell

Share:
esg
esg
esg
esg

Investors Headlines

Driving Change: SSGA Rolls Out Sustainability-Focused Proxy Voting Framework

Driving Change: SSGA Rolls Out Sustainability-Focused Proxy Voting Framework

UK Banks Linked to £75bn in Fossil Fuel Projects Abroad

UK Banks Linked to £75bn in Fossil Fuel Projects Abroad

Poet Stock 2025: Sustainability Meets Smart Investing

Thailand Launches ESGX Tax Incentives and LTF Transfer Portal to Boost Green Investments

U.S.'s First ESG-Focused Stock Exchange to be Launched in 2026

Climate Tech Investment Rebounds in US: Silicon Valley Bank Report

ISS STOXX New Rating Assesses Green Bond Risk at Issuance Level

Sironix Raises $3.5M for Renewable Chemicals Sector

Reask Raises USD 4M to Provide Accurate Climate Risk Data

Terabase Raises $130M to Expand Solar Digitization and Automation